Brief: Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (Rmat) Designation From FDA For Ft819 To Treat Moderate To Severe Systemic Lupus Erythematosus (Sle)
14/04/2025 15:08
April 14 (Reuters) - Fate Therapeutics Inc FATE.O: FATE THERAPEUTICS RECEIVES REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION FROM FDA FOR FT819 TO TREAT MODERATE TO SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) Source text: ID:nGNXg383W Further company coverage: FATE.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fate Therapeutics
See all newsBrief: Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial Of FT819 For The Treatment Of Lupus Nephritis
Fate Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Fate Therapeutics Q2 loss narrows as expenses fall, revenue rises
Fate Therapeutics Inc expected to post a loss of 27 cents a share - Earnings Preview
Fate Therapeutics Inc expected to post a loss of 27 cents a share - Earnings Preview